Skip to content
PubMed This is a summary of 48 peer-reviewed journal articles Updated
Hematology

Cold Agglutinin Disease (CAD): A Patient Guide

At a Glance

Cold agglutinin disease is an autoimmune blood disorder in which cold-sensitive antibodies damage red blood cells. Management includes avoiding cold, using warmed testing and transfusions when needed, and medicines that target the abnormal cells or immune destruction.

Cold Agglutinin Disease (CAD) is a rare type of autoimmune hemolytic anemia where your immune system mistakenly identifies your red blood cells as foreign and destroys them. The hallmark of this condition is its sensitivity to temperature: the antibodies responsible for the destruction, called cold agglutinins, typically activate and attach to your red blood cells when they are exposed to cooler temperatures [1][2]. Once these antibodies attach, they trigger a series of immune proteins called the complement system, which tags the cells for removal by your liver or causes them to break apart directly in your bloodstream [2][3].

Your medical team will distinguish between two forms of this condition: Primary CAD and Secondary Cold Agglutinin Syndrome (CAS). Primary CAD is considered its own standalone disease, caused by a slow-growing group of cells (a B-cell clone) in your bone marrow that produces the cold-sensitive antibodies [4][1]. In contrast, Secondary CAS is a side effect of another health issue, such as a recent infection like pneumonia or mono, or an underlying condition like lymphoma [3]. Identifying which form you have is the first step in creating an effective care plan, as the cause dictates how the condition is managed.

Living with CAD requires a new level of vigilance regarding temperature and medical care. Because your blood can “clump” and break down when chilled, you may experience profound fatigue from anemia or circulatory issues like fingers and toes turning blue in the cold [5][6]. You may also face a higher risk of blood clots, making it vital to stay active and monitor for unusual swelling or pain [7]. One of the most important things you can do as a patient is to ensure your specific medical samples (like cold-agglutinin titers) and any necessary blood transfusions are handled with specialized warming protocols, as standard lab procedures can sometimes lead to inaccurate results or adverse reactions, though you should never delay life-saving care [8][9].

While a rare diagnosis can feel isolating, CAD is a condition that can often be managed effectively. Many patients find success through a combination of lifestyle changes—such as sensible cold avoidance—and modern medical therapies that either target the B-cell clone or block the complement system’s ability to destroy red blood cells [5][10]. By understanding the biology of your condition and advocating for the specialized care it requires, you can take control of your health and maintain a high quality of life.

Common questions in this guide

What is the difference between primary CAD and secondary cold agglutinin syndrome?
Primary cold agglutinin disease is a standalone condition in which a slow-growing group of bone marrow B cells makes cold-sensitive antibodies. Secondary cold agglutinin syndrome happens because of another problem, such as an infection or lymphoma. The distinction helps guide treatment.
Why do cold temperatures make CAD symptoms worse?
Cold-sensitive antibodies attach to red blood cells when they are chilled and activate immune proteins that can clump or destroy those cells. This can worsen anemia-related fatigue and cause fingers or toes to turn blue. Sensible cold avoidance can reduce exposure, but it should not replace medical care.
Why do CAD blood tests need special handling?
Cold agglutinin measurements and some related blood samples may need to be kept warm from collection through processing. Chilling can change the sample and lead to inaccurate results. Ask your care team how your laboratory handles these tests.
What should the hospital blood bank know if I need a transfusion with CAD?
Tell the hospital and blood bank that you have cold agglutinin disease so they can use the appropriate warming procedures for testing and transfusion. These precautions help reduce problems caused by cold-sensitive antibodies. Emergency, life-saving transfusions should not be delayed while special handling is arranged.
When is medication considered for cold agglutinin disease?
Treatment decisions depend on how severe the anemia is, which symptoms you have, how active the disease appears, and whether the condition is primary or secondary. If lifestyle measures are not enough, treatment may target the abnormal B-cell group or the immune pathway that destroys red blood cells. Your clinician can discuss when drug treatment is appropriate for you.
Does CAD increase the risk of blood clots?
Cold agglutinin disease can increase the risk of blood clots. Staying active as advised and reporting unusual swelling or pain to your medical team can help address possible complications early. Your clinician can explain which symptoms need urgent evaluation.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Cold agglutinin disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Have we definitively determined if I have primary Cold Agglutinin Disease (CAD) or secondary Cold Agglutinin Syndrome (CAS)?
  2. 2.Do my lab records confirm that my CAD-specific blood samples were kept warm to ensure accurate results?
  3. 3.How will we decide when my anemia or symptoms are severe enough to move from lifestyle adjustments to drug treatment?
  4. 4.What is the plan for communicating with the hospital's blood bank if I ever need an emergency transfusion?
  5. 5.What are the specific markers and symptoms we will use to monitor my disease activity over the long term?

References

References (10)
  1. 1

    Diagnosis and management of cold agglutinin disease.

    Berentsen S

    Hematology. American Society of Hematology. Education Program 2025; (2025(1)):295-304 doi:10.1182/hematology.2025000718.

    PMID: 41348049
  2. 2

    Cold agglutinin disease: pathophysiology, diagnosis, and the evolving therapeutic landscape.

    Choi DH

    Blood research 2026; (61(1)).

    PMID: 42696222
  3. 3

    New Insights in the Pathogenesis and Therapy of Cold Agglutinin-Mediated Autoimmune Hemolytic Anemia.

    Berentsen S

    Frontiers in immunology 2020; (11()):590 doi:10.3389/fimmu.2020.00590.

    PMID: 32318071
  4. 4

    Cold-antibody Autoimmune Hemolytic Anemia: its Association with Neoplastic Disease and Impact on Therapy.

    Berentsen S

    Current oncology reports 2024; (26(9)):1085-1096 doi:10.1007/s11912-024-01569-8.

    PMID: 38874820
  5. 5

    [Cold agglutinin disease (CAD)].

    Röth A, Borchert K, Dorn C, et al.

    Innere Medizin (Heidelberg, Germany) 2025; (66(9)):986-996 doi:10.1007/s00108-025-01926-0.

    PMID: 40691722
  6. 6

    How I manage patients with cold agglutinin disease.

    Berentsen S

    British journal of haematology 2018; (181(3)):320-330 doi:10.1111/bjh.15109.

    PMID: 29363757
  7. 7

    Increased risk of thrombotic events in cold agglutinin disease: A 10-year retrospective analysis.

    Broome CM, Cunningham JM, Mullins M, et al.

    Research and practice in thrombosis and haemostasis 2020; (4(4)):628-635 doi:10.1002/rth2.12333.

    PMID: 32548562
  8. 8

    [Cold agglutinin disease: pathology, diagnosis, and treatment].

    Wada H

    [Rinsho ketsueki] The Japanese journal of clinical hematology 2024; (65(6)):521-528 doi:10.11406/rinketsu.65.521.

    PMID: 38960651
  9. 9

    IgA plasma cell myeloma presenting as cold agglutinin-induced haemolytic transfusion reaction.

    Mehdipour Dalivand M, Woddor N, Makuria A, et al.

    BMJ case reports 2024; (17(2)) doi:10.1136/bcr-2022-251638.

    PMID: 38423573
  10. 10

    Sutimlimab: First Approval.

    Dhillon S

    Drugs 2022; (82(7)):817-823 doi:10.1007/s40265-022-01711-5.

    PMID: 35412113

This page is for informational purposes about cold agglutinin disease and does not constitute medical advice. Your treating clinician and blood bank should guide decisions about testing, transfusions, and treatment for your situation.